DUGiDocsEffectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
Text Complet
Purpose: Atrial fibrillation is the most common
arrhythmia. Its management aims to reduce symptoms
and to prevent complications through rate and rhythm
control, management of concomitant cardiac diseases
and prevention of related complications, mainly stroke.
The main objective of Effectiveness, Safety and Costs
in Atrial Fibrillation (ESC-FA) study is to analyse the
drugs used for the management of the disease in realuse
conditions, particularly the antithrombotic agents
for stroke prevention. The aim of this work is to
present the study protocol of phase I of the ESC-FA
study and the baseline characteristics of newly
diagnosed patients with atrial fibrillation in Catalonia,
Spain.
Participants: The data source is System for the
Improvement of Research in Primary Care (SIDIAP)
database. The population included are all patients with
non-valvular atrial fibrillation diagnosis registered in the
electronic health records during 2007–2012.
Findings to date: A total of 22 585 patients with
non-valvular atrial fibrillation were included in the
baseline description. Their mean age was 72.8 years
and 51.6% were men. The most commonly prescribed
antithrombotics were vitamin K antagonists (40.1% of
patients) and platelet aggregation inhibitors (32.9%);
25.3% had not been prescribed antithrombotic
treatment. Age, gender, comorbidities and comedication
at baseline were similar to those reported
for previous studies.
Future plans: The next phase in the ESC-FA study
will involve assessing the effectiveness and safety of
antithrombotic treatments, analysing stroke events and
bleeding episodes’ rates in our patients (rest of phase
I), describing the current management of the disease
and its costs in our setting, and assessing how the
introduction of new oral anticoagulants changes the
stroke prevention in non-valvular atrial fibrillation
Aquest document està subjecte a una llicència Creative Commons:Reconeixement - No comercial (by-nc)
